Roche's Genentech to Take Part in First-ever Alzheimer's Prevention Trial
Published: May 21, 2012
Roche Holding AG's Genentech unit has won the right to try its experimental Alzheimer's drug crenezumab on people with no signs of dementia - the first such trial to gauge whether early intervention can help prevent or slow the disease. The drug will be tested among members of an extended family of about 5,000 people from the Antioquia region of Colombia. They carry a gene that causes them to develop Alzheimer's early, with some experiencing symptoms of memory loss in their mid-30s, scientists say.